Missing In Action: China’s Best Shot In Ebola Vaccine Race
Executive Summary
As the Congo grapples with the latest outbreak of Ebola, China has approved its first domestically developed vaccine in record time, hailing it a national innovation champion. But as the World Health Organization starts vaccinations in Africa, can China make the cut and compete with global players including Merck & Co?
You may also be interested in...
Ebola Outbreak In DR Congo: Where Are The Vaccines In Development?
Following reports of another Ebola outbreak in Africa, Scrip explores the pipeline of clinical-stage vaccines and how the companies developing immunizations are approaching the most recent cases of the viral hemorrhagic disease.
Sanofi, Innovent Link On China Oncology Ambitions As ADCs Surge
The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.
China-US Tensions Rise Sharply On Pelosi Visit, Will Biotech Get Burned?
Where once there were promising prospects for cross-strait collaboration, biopharma firms in mainland China and Taiwan may now find themselves looking elsewhere for partners following a controversial visit to Taipei by US House Speaker Nancy Pelosi.